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extra-colonic feature of FAP in the Western world. It seems 
to present at an advanced stage with a poor prognosis. 
There may be an association between gastric tumour and 
desmoid occurrence but a large multicentre cohort is neces-
sary to investigate this further.
Keywords Gastric cancer · Gastric adenoma · Desmoid · 
Familial adenomatous polyposis
Introduction
Familial adenomatous polyposis (FAP) is a rare autosomal 
dominantly inherited condition due to a germline mutation 
in the APC gene. It is a cancer predisposing syndrome that 
typically results in the development of hundreds to thou-
sands of colorectal adenomas that inevitably progress to 
cancer by the age of 40 years without prophylactic colec-
tomy or proctocolectomy [1]. Although the colorectal 
manifestations of FAP predominate, the condition is also 
associated with the development of several other tumours. 
Duodenal cancer and desmoid tumours are the leading 
cause of morbidity and mortality in this population once 
the colorectal cancer risk has been addressed [2, 3].
Gastric cancer is not a prominent extra-colonic manifes-
tation of FAP in the Western world. The risk of develop-
ing gastric cancer in this patient group is reportedly similar 
to that of the general population and less than 1% [4–6]. 
However, in Korea and Japan, where gastric cancer is more 
prevalent, it does seem to be associated with FAP, and the 
risk is seven to tenfold of that seen in the respective gen-
eral populations [7–10]. The risk of gastric adenoma devel-
opment in patients with FAP shows a similar increase in 
Asian populations compared to the Western world. Simi-
larly, the risk of gastric adenoma development in patients 
Abstract Gastric cancer is not a recognised extra-colonic 
manifestation of FAP, except in countries with a high prev-
alence of gastric cancer. Data regarding gastric adenomas 
in FAP are sparse. The aim of this study was to review the 
clinical characteristics of gastric tumours occurring within 
an FAP population from the largest European polyposis 
registry. All patients that developed a gastric adenoma or 
carcinoma were identified from a prospectively maintained 
registry database. The primary outcome measure was the 
occurrence of gastric adenoma or adenocarcinoma. Sec-
ondary outcomes included APC mutation, tumour stage, 
management and survival. Eight patients developed gastric 
cancer and 21 an adenoma (median age 52 and 44 years, 
respectively). Regular oesophagogastroduodenoscopy sur-
veillance was performed in 6/8 patients who developed can-
cer. Half were advanced T3/4 tumours and 6/8 had nodal or 
metastatic spread at diagnosis. All cancer cases died within 
a median of 13.5 months from diagnosis. Gastric adeno-
mas were evenly distributed: 11/21 (52%) in the distal and 
10/21 (48%) proximal stomach, whereas 5/8 (63%) cancers 
were located proximally. An association between gastric 
tumour and desmoid development was observed; 7/8 (88%) 
cancer and 11/21 (52%) adenoma cases had a personal or 
family history of desmoid. It would appear from this small, 
retrospective study that gastric cancer is not a prominent 
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with FAP is lower in the Western world compared to Asian 
populations. In the West, gastric adenomas are reported 
to occur in 2–10% of patients [11–13] but ranges between 
15–50% in Asian populations [14–17].
Studies that describe the clinical features of gastric 
lesions occurring in association with FAP in Western 
populations are lacking. One such study reported upper GI 
lesions in FAP and detected gastric dysplasia in only 6 of 
102 patients studied endoscopically, with a predilection for 
the antrum [18]. The largest study in the Western world to 
report gastric adenoma occurrence involved only 9 cases 
[13]. The aim of this descriptive study was to report the 
clinical features of gastric adenomas and carcinomas aris-
ing in patients with FAP attending our institution.
Methods
All histologically confirmed gastric adenocarcinoma cases 
were identified from the polyposis registry database. Upper 
GI tract endoscopic surveillance was introduced in 1974 
and gastric adenomas discovered between 1974 and 2015 
were identified from the same database. Medical notes, 
imaging, endoscopy and pathology reports were obtained 
and further scrutinised. Data gathered included patient 
demographics, APC mutation, tumour location, histology 
and stage, intervention undertaken and survival outcome. 
Gastric lesions were classified as proximal or distal, rela-
tive to the gastric incisura.
Permission was obtained to access and utilise data 
from an international FAP database held by the Interna-
tional Society for Gastrointestinal Hereditary Tumours 
(InSiGHT) group. This database provided a large FAP 
cohort that could be used to identify further gastric cancer 
cases and provide a spectrum and frequency of mutations 
in FAP overall to compare with our gastric adenoma and 
cancer group. This database was larger and less likely to 
be biased. Gastric cancer cases obtained from this database 
were only used for APC mutation evaluation and excluded 
from other clinical analyses as these data were largely una-
vailable from the database. Entries with ambiguous termi-
nology (for example ‘atypical FAP’) were excluded from 
the study. In FAP approximately 95% of germline APC 
mutations are frameshift or nonsense mutations, result-
ing in a truncated protein with an abnormal function [19]. 
Large APC mutations that would not allow genetic analy-
sis when searching for a potential mutation cluster region 
for gastric cancer were excluded, as were all silent and 
missense mutations. Only those mutations that would pre-
dict truncation of the APC protein (non-sense, frameshift 
and splicing mutations) were included. The site of the 
APC germline mutation determines that of the ‘second 
hit’ mutation, resulting in an optimal level of beta-catenin 
activity [20]. These ‘first hit-second hit’ associations can 
influence phenotype, with germline mutations 3′ of codon 
1400 resulting in more upper gastrointestinal lesions and 
desmoid tumours [21, 22].
Gastric adenoma cases were not obtained from the 
InSiGHT database as these were not routinely reported and 
detailed pathology findings were unavailable.
APC mutations in the gastric cancer group were ana-
lysed to determine the spectrum of sites involved. If a gas-
tric cancer genotype/phenotype correlation exists, it would 
most likely occur within this area of the gene. The propor-
tion of APC mutations in the control group lying within 
and outside of this region was then recorded and compared 
to the gastric adenoma and cancer groups.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 
(GraphPad, San Diego, CA). For analysis a p-value of less 
than 0.05 was considered significant.
Results
A search of the polyposis registry database revealed eight 
cases of gastric cancer and 21 patients with gastric adeno-
mas. An exact denominator is not possible to define. How-
ever, 1435 patients were registered who have had all, or at 
least part of their care at our institution. The majority of the 
patients were of white European ethnicity with a minority 
originating from the Indian subcontinent.
Clinical features of gastric adenocarcinomas
Eight British Caucasian patients (five female) known to the 
polyposis registry developed gastric cancer (Table 1). The 
median age at diagnosis was 52 years (range 41–64). Two 
patients were asymptomatic and diagnosed at the time of 
their surveillance OGD. Half of patients presented with 
anaemia, one of whom had recurrent bleeding through a 
jejunostomy. Abdominal pain was a presenting feature in 
only two cases.
Despite 6/8 patients undergoing regular upper GI endo-
scopic surveillance for their FAP, half of these patients 
presented with advanced tumours, stage T3 or T4. All 
of these advanced lesions, along with a T2 tumour, were 
associated with metastatic disease at the time of diagno-
sis. All patients had extensive cystic gland polyps carpet-
ing the stomach but no gastric adenomas were reported 
from histology obtained at endoscopy. Most tumours were 
located in the proximal stomach (fundus n = 1, cardia n = 1 
and body n = 3) with only two located in the antrum. The 
two most proximal tumours were T3 and T4 stage, while 
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the three tumours located in the stomach body were all T2. 
Distally one tumour was only T1 and the other T3.
Treatment for gastric cancer comprised chemotherapy 
alone for half of the patients, who all had metastatic and/or 
nodal disease. Surgery was performed in three cases: a par-
tial and total gastrectomy for the T1 and T2 tumours with-
out nodal or metastatic disease and a sleeve gastrectomy for 
a T3 tumour with metastatic disease that was diagnosed at 
the time of the surgery to stem ongoing blood loss (previ-
ous biopsies had all been benign). One patient with a T4 
tumour and widespread metastatic disease received sup-
portive care for their gastric tumour.
Median survival from diagnosis was 13.5 months (range 
2–101) and all patients eventually died as a direct result of 
their gastric cancer.
Seven out of eight (88%) patients had significant duo-
denal polyposis (Spigelman stage III–IV disease), although 
information was unavailable for the remaining patient. 
Seven patients (88%) had a personal history or family his-
tory of a desmoid tumour.
Gastric adenoma cases
Twenty-one (11 male) patients with gastric adenoma were 
identified from the registry database and all were of Brit-
ish Caucasian ethnicity. The median age at detection was 
44-years (range 23–71), eight years younger than that for 
gastric adenocarcinoma (Table  1). Histology found 18 
(86%) of lesions were tubular adenomas (TA) and three 
were tubulovillous adenomas (TVA). Eighteen (86%) had 
low grade dysplastic lesions and three (14%) had high-
grade dysplasia; all of the lesions which contained high 
grade dysplasia were detected in the proximal stomach. 
Adenomas were found almost equally in the proximal 
(n = 10, 48%) and distal stomach (n = 11, 52%). Proximal 
lesions were usually a pale, creamy coloured flat plaque, 
whereas the antral lesions were more pinkish and elevated. 
All gastric adenomas larger than 2 cm were located in the 
proximal stomach. In eight out of 21 (38%) cases multiple 
adenomas were identified. In 7/8 of these cases the adeno-
mas were located within the same region but for one case 
an adenoma was found in both the fundus and antrum.
Patients who developed gastric cancer had more 
advanced duodenal polyposis (Spigelman stage III or IV 
disease) compared to the adenoma group, 7/8 (88%) and 
10/21 (47%), respectively (Logrank test χ2 = 14.63 (2df), 
p = 0.0007). However, this may be explained by the age dis-
crepancy between the two cohorts. Indeed, in the adenoma 
group the median age of those with Spigelman stage III or 
IV duodenal disease was 49 years compared to 40 years for 
those with stage 0–II disease.
Ten (47%) of the gastric adenoma cohort had Spigelman 
III or IV disease. A personal or family history of desmoid 
disease was observed in 11/21 (52%).
To date no patients have required surgery for gastric ade-
nomas. One patient has been lost to follow up. All other 
patients have been managed endoscopically and have either 
had (9/21 (43%)) or are awaiting endoscopic resection of 
their gastric adenoma.
APC mutation analysis
Further analysis of the APC mutation distribution was 
undertaken comparing patients with gastric cancers and 
gastric adenomas with controls with FAP but no reported 
gastric pathology obtained from the InSiGHT database. A 
total of 3012 patients were identified from the InSiGHT 
database and were of predominantly European ethnicity, 
of which one had gastric cancer and 38 were recorded as 
having possible gastric adenoma. These 38 patients were 
not included in the adenoma group analysis as detailed 
Table 1  Clinical data comparing gastric adenoma and gastric adeno-
carcinoma cases in patients with FAP
*Fisher’s exact test, **Mann Whitney-U test, +χ2 test
Gastric 
adenomas 
n = 21 (%)
Gastric cancers n = 9 
(%)
p value
Gender
 Male 11 (52) 3 (38) 0.70*
 Female 10 (48) 5 (62)
Median age at 
diagnosis, years 
(range)
44 (23–71) 52 (41–64) 0.06**
Location and T-stage
 Cardia 1 (5) 1 (13) T3
 Fundus 5 (24) 1 (13) T4 0.48+
 Body 4 (19) 3 (37) T2
 Antrum 11 (52) 2 (25) T1,T3
 Unknown 1 (13) T4
Spigelman stage
 0–II 11 (52) 0
 III 7 (33) 1 (13) 0.0007+
 IV 3 (14) 6 (75)
 Unknown 1 (13)
Desmoid tumour history
 Personal 9 (43) 5 (62)
 Family 2 (9) 2 (25) 0.14*
 Neither 10 (48) 1 (13)
APC mutation distribution
 Codon range 233–1461 685–2040
 3′ of codon 1390 2 (10) 6 (67) 0.005*
 5′ of codon 1390 17 (81) 3 (33)
 Unknown 1
 Excluded 1
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histology reports were not available to confirm these find-
ings. The adenoma cases from the polyposis registry data-
base were compared with the remaining 2974 FAP control 
cases from the InSiGHT database. For one gastric adenoma 
case the APC mutation was not known and in another case 
was a large deletion of Exon 1–5. This was excluded from 
APC mutations analysis as this would null the gene rather 
than produce a truncating protein and could not be used to 
compare potential phenotypes.
All gastric cancer cases had germline mutation between 
codons 685 and 2040, whereas only 64% of controls cases 
had a mutation found within this region (Table 2; Fig. 1). 
Only 10/21 (48%) of patients with a gastric adenoma had 
an APC mutation in this region (Table  3). Gastric cancer 
cases were significantly more likely to have a mutation 3′ of 
codon 1390 compared to controls, 6/9 (67%) and 399/3012 
(13%) (p = 0.0003), respectively; this is close to the region 
associated with a higher risk for desmoid development [23]. 
Germline mutation in adenoma cases had a similar distri-
bution to that in controls (2/21 (10%) 3′ of codon 1390).
Discussion
This study reports the clinical features and outcomes from 
a rare cohort of patients with FAP and gastric cancer within 
a predominantly European population. There are no other 
descriptive studies of gastric cancer in patients with FAP 
in the Western world. The only study to report the clinical 
characteristics of gastric cancers occurring in FAP origi-
nates from a Japanese population with distinct differences 
from our data [10]. This study reported on five patients and 
found three had multifocal disease whereas in our series all 
eight had a single focus of tumour. We also reported that 
more were located in the proximal stomach whereas there 
was no clear distribution for the Japanese tumours. In addi-
tion, our study found most gastric cancers presented late 
Table 2  Comparing frequency of APC mutations within and outside 
of the region for gastric cancer mutations with FAP controls
*Fisher’s exact test
APC mutation (codon) Controls, n (%) Gastric cancer 
cases, n (%)
p value
5′ of 685/3′ of 2040 1107 (37) 0 0.03*
Between 685 and 2040 1905 (63) 9 (100)
5′ of codon 1390 2613 (87) 3 (33) 0.0003*
3′ of codon 1390 399 (13) 6 (67)
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Fig. 1  Graph demonstrating the distribution of APC 5′ to 3′ mutations, InSiGHT and SMH (St Mark’s Hospital) FAP, gastric cancer and ade-
noma databases
Table 3  Comparing frequency of APC mutations within and outside 
of the region for gastric cancer mutations between FAP controls and 
gastric adenoma cases
a Fisher’s exact test
APC mutation (codon) Controls, n (%) Gastric adenomas p value
5′ of 685/3′ of 2040 1096 (37) 9 (43) 0.35a
Between 685 and 2040 1878 (63) 10 (48)
Unknown 1
Excluded 1
5′of codon 1390 2576 (87) 17 (81) 1a
3′of codon 1390 398 (13) 2 (10)
Unknown 1
Excluded 1
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in their course whereas in the Japanese group they were 
detected at an earlier stage.
This was a small series but it supports previous study 
findings that gastric cancer is not a significant extra-colonic 
manifestation of FAP in the West [4, 5]. In contrast, Park 
et al. found the incidence of gastric adenomas was 14% and 
gastric cancers nearly 3% in Korean patients with FAP [14].
We found gastric cancer occurred at a relatively young 
age (median age of 52 years), presented with subtle signs 
or without any symptoms at all, and had a dismal progno-
sis. Three-quarters of the patients in our cohort presented 
with advanced tumours at diagnosis, despite the major-
ity undergoing endoscopic surveillance. This may indi-
cate a significant gastric adenoma and carcinoma miss 
rate. It is important to note that extensive carpeting by 
cystic gland polyps occurred in these cases and this may 
have hindered prompt gastric cancer diagnosis by obscur-
ing the presence of tumour. However, most tumours were 
located in the body and fundus, including two of the three 
advanced T3/4 tumours. In our experience, adenomas in 
this region have a subtle pale plaque-like appearance that 
can be more difficult to detect endoscopically than the 
sessile pink polypoid lesions that were usually found in 
the antrum (Figs. 2, 3), further impeding the pick-up rate 
for proximal lesions. Ngamruengphong et  al. reported 
a significant adenoma miss rate at endoscopy affecting 
6/9 patients [13]. A recent systematic review and meta-
analysis reported an endoscopic miss rate for the detec-
tion of gastric cancers in a non-FAP population as high 
as 10%, particularly when lesions were located in the 
body [24]. Advances in endoscopic equipment, training 
and techniques are likely to have improved our ability 
to detect subtle plaque-like lesions that may have been 
missed previously. This is supported by the findings from 
our study that the majority of gastric adenomas (15/21) 
were detected in recent years (between 2013 and 2015). 
Because of these issues it is impossible to quantify the 
prevalence of gastric adenomas in patients with FAP. It 
is also difficult to extrapolate their clinical course. It is 
likely that they have a relatively benign clinical course, 
that may be analogous to the duodenal adenoma, how-
ever, the occurrence of three adenomas with high grade 
dysplasia in this study highlights the malignant potential 
of these lesions.
A significant difference was noted between the can-
cer group and adenoma group regarding the presence of 
advanced duodenal disease (Spigelman III/IV). Advanced 
duodenal disease was seen more commonly in the can-
cer group (88%) than the adenoma group (47%). The two 
groups however are not age matched (the median age of 
adenoma group was eight years younger than the cancer 
group) and therefore it is difficult to comment further on 
whether or not there is an association between gastric can-
cer and duodenal disease in FAP. To explore further a pos-
sible association between gastric adenomas and/or cancer 
with duodenal disease would require a large, age matched 
control group for comparison. Spigelman et al. previously 
reported that patients with gastric adenomas had a higher 
incidence of severe duodenal polyposis [18]. A more 
recent study by Ngamruengphong et  al. failed to show an Fig. 2  A subtle plaque-like gastric adenomas at the fundus
Fig. 3  Polypoid antral adenomas
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association between gastric adenomas and duodenal dis-
ease in FAP [13].
An interesting finding from this study was the possi-
ble association between gastric cancer development and 
a history of desmoid tumour. Sixty-two per cent of these 
patients had a desmoid tumour, a significantly higher rate 
than typically reported in patients with FAP (up to 25%) 
[23, 25] (p = 0.036), Fisher’s exact test. If such an associa-
tion were real it could suggest a genotype-phenotype cor-
relation for gastric cancer occurrence in FAP exists, in the 
same way as for desmoid tumours [26]. They may share a 
common region or overlap at a particular point on the APC 
gene (for example 3′ of codon 1399 for desmoids and 1390 
for gastric cancer). Significantly more germline mutations 
were identified 3′ of codon 1390 in the gastric cancer group 
compared to controls. Another explanation could be that 
both groups share a common modifier gene.
It would seem logical that gastric adenomas, (if they 
are the pre-malignant lesion responsible for gastric cancer 
development in FAP), would demonstrate similar findings. 
Indeed, a greater proportion of gastric adenoma cases than 
would normally be expected had a personal or family his-
tory of desmoid. Interestingly, Ngamruengphong et al. also 
reported that patients with FAP and a gastric adenoma were 
significantly more likely to have had a desmoid tumour 
compared to patients without a history of a gastric ade-
noma, 5/9 (56%) and 19/88 (22%), respectively [13]. This 
was comparable to our study’s findings. Case reports have 
also described an association between gastric cancer and 
desmoid tumour development following gastrectomy [27, 
28].
The germline APC mutation distribution in gastric can-
cer cases differs from that seen in gastric adenomas, which 
more closely reflects the control FAP group. The mutation 
clustering seen in gastric cancer cases may therefore be an 
anomalous finding due to the small numbers of patients 
in this cohort. The observation of an association despite 
the differences in germline mutation distribution could 
also indicate an association between gastric neoplasia and 
desmoid disease which is independent of the germline 
mutation.
The retrospective nature of this study is a limitation, 
despite the data being collected prospectively. In a few 
instances, patients with FAP will undergo upper GI sur-
veillance locally, rather than the tertiary centre. This might 
lead to fewer adenoma cases being identified through the 
registry database then would normally occur if undertaken 
at the tertiary centre. Despite this, most patients undergo 
their routine FAP follow-up at this institution and therefore 
OGD reports from local institutions are usually obtained 
by the polyposis registry. Certainly, the development of a 
gastric cancer is unlikely to occur without the tertiary cen-
tre being aware. The InSiGHT database contained a large 
FAP cohort but it was not possible to include those patients 
labelled as ‘gastric adenoma’ in the adenoma group analysis 
as there were insufficient data regarding histology details to 
be sure they were true gastric adenoma cases. Referral bias 
is unlikely to have occurred as the tertiary hospital is not 
an upper GI cancer centre and therefore patients would not 
have been referred specifically for the purpose of managing 
their gastric adenoma or cancer.
The strengths of this study include the polyposis regis-
try database that has existed for over 90 years, providing 
one of the largest cohorts of patients with FAP for the study 
of this rare disease. Access to the InSiGHT database also 
provided thousands of FAP ‘control’ cases without gastric 
lesions. This was an invaluable resource for studying APC 
mutations in this group.
Conclusion
This is the largest series to report on gastric adenomas and 
gastric cancers occurring in association with FAP in the 
Western World. Unlike Far East populations, gastric cancer 
is not a feature of FAP and when diagnosed they are often 
advanced, despite OGD surveillance, and associated with 
a poor prognosis. There may be an association between 
the development of gastric adenomas or gastric cancers 
and desmoid tumours in FAP. Although the existence of 
a gastric-cancer genotype-phenotype correlation seemed a 
possibility, this was not supported in the adenoma group. 
To determine the true significance of these findings a much 
larger cohort is necessary, requiring a considerable interna-
tional, multi-centre, collaborative effort.
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